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ABSTRACT Serine-arginine (SR) protein kinase 1 (SRPK1) catalyzes the phosphoryla-
tion of SR proteins, which are a conserved family of splicing factors that contain a
domain rich in arginine and serine repeats. SR proteins play important roles in con-
stitutive pre-mRNA splicing and are also important regulators of alternative splicing.
During herpes simplex virus infection, SRPK1 is inactivated and its cellular distribu-
tion is markedly altered by interaction with the viral protein ICP27, resulting in hy-
pophosphorylation of SR proteins. Mutational analysis previously showed that the
RGG box motif of ICP27 is required for interaction with SRPK1; however, the mecha-
nism for the inhibition and the exact role of the RGG box was unknown. Here, we
used solution nuclear magnetic resonance (NMR) spectroscopy and isothermal titra-
tion calorimetry (ITC) to demonstrate that the isolated peptide comprising the RGG
box of ICP27 binds to SRPK1 with high afﬁnity, competing with a native substrate,
the SR repeat region of SR protein SRSF1. We determined the crystal structure of the
complex between SRPK1 and an RGG box peptide, which revealed that the viral
peptide binds to the substrate docking groove, mimicking the interactions of SR re-
peats. Site-directed mutagenesis within the RGG box further conﬁrmed the impor-
tance of selected arginine residues for interaction, relocalization, and inhibition of
SRPK1 in vivo. Together these data reveal the molecular mechanism of the competi-
tive inhibition of cellular SRPK1 by viral ICP27, which modulates SRPK1 activity.
IMPORTANCE Serine arginine (SR) proteins are a family of mRNA regulatory proteins
that can modulate spliceosome association with different splice sites and therefore
regulate alternative splicing. Phosphorylation within SR proteins is necessary for
splice-site recognition, and this is catalyzed by SR protein kinase 1 (SRPK1). The her-
pes simplex virus (HSV-1) protein ICP27 has been shown previously to interact with
and downregulate SRPK1 activity in vivo; however, the molecular mechanism for this
interaction and inhibition was unknown. Here, we demonstrate that the isolated
peptide fragment of ICP27 containing RGG box binds to SRPK1 with high afﬁnity,
and competes with a native cellular substrate. Elucidation of the SRPK1-RGG box
crystal structure further showed that a short palindromic RGRRRGR sequence binds
in the substrate docking groove of SRPK1, mimicking the binding of SR repeats of
substrates. These data reveal how the viral protein ICP27 inactivates SRPK1, promot-
ing hypophosphorylation of proteins regulating splicing.
KEYWORDS phosphorylation, splicing, herpes simplex virus, structure,
phosphorylation, SR protein kinase
Alternative pre-mRNA splicing is a fundamental mechanism that increases thediversity of protein isoforms expressed by eukaryotes, and defects in its regulation
are associated with multiple disorders, including cancer (1, 2). Serine-arginine (SR)
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splicing factors modulate spliceosome association with different splice sites and there-
fore regulate alternative splicing (3). One of the key regulators of SR protein activity in
humans is serine-arginine protein kinase 1 (SRPK1), which phosphorylates SR repeat
sequences of SR proteins promoting both their localization in the nucleus and splicing
activity (4–6). Often more than one string of SR repeats are clustered together sepa-
rated by short non-SR sequences in regions termed RS domains. The structure of SRPK1
is composed of an N-terminal domain containing the active site linked to a C-terminal
domain that forms a docking groove, which recognizes SR repeats (7, 8). Substrates
such as the prototype SR protein SRSF1 (ASF/SF2) bind tightly to the SRPK1 docking
groove, with a dissociation constant of the order of 50 nM (9–11). SRPK1 can phos-
phorylate multiple SR repeats, using a processive mechanism whereby the substrate
peptide slides through the docking groove toward the ATP binding pocket in a C- to
N-terminal direction (4, 12–14). Alternatively, SRPK1 can also use a distributive mech-
anism, in which the enzyme recognizes short SR sequences, phosphorylates them, and
dissociates from a substrate (4). The distributive mechanism has been characterized in
the SR protein Tra2, which contains only a tetra-SR repeat and isolated SR dipeptides,
and mutagenesis experiments indicated that the SRPK1 docking groove was dispens-
able for this mode of catalysis (15).
SRPK1 also acts with other cellular SR protein kinases, which provide an additional
layer of regulation by tuning substrate regiospeciﬁc phosphorylation and nuclear-
cytoplasmic distribution. For example, the octa-SR repeat containing the N-terminal
half of the RS domain of SRSF1 is phosphorylated by SRPK1, whereas a different kinase
from the CLK family acts on the C-terminal half (16, 17). SRPK1 does not contain a
nuclear localization sequence (NLS), so it is predominantly cytoplasmic and SR phos-
phorylation facilitates SR protein nuclear import via a speciﬁc transportin protein
(18–20). Subsequently CLKs (which have an NLS) phosphorylate SR proteins in the
nucleus. Additionally CLKs can also bind SRPK1 and facilitate the latter’s passage into
the nucleus, where the interaction of SRPK1 with CLKs facilitates the release of SR
proteins from CLK1 (21). Therefore, the ternary mixture of SRPK1, CLKs, and SR proteins
affects the latter’s cellular distribution and regiospeciﬁc phosphorylation, which mod-
ulates recognition of splice sites and in turn recruits spliceosome proteins thus medi-
ating alternative splicing (21, 22). SRPK1 action on SR proteins has also been shown to
facilitate angiogenesis and neovascularization by promoting the production of proan-
giogenic isoforms of the vascular endothelial growth factor (VEGF) and therefore was
recognized as a promising drug target for a variety of diseases associated with
deregulated alternative splicing (1, 23). SRPK1 also acts as a general signal modulator
besides its role in regulated splicing. Another regulatory role of SRPK1 is its interaction
with Akt kinases, which are active as phosphoproteins, and also PHLPP1, a phosphatase
that inactivates Akt (24). Aberrant SRPK1 expression can lead to cancer progression.
SRPK1 underexpression leads to Akt hyperactivation due to a lack of the downregula-
tory ternary complex formation with PHLPP1. Conversely, overexpression of SRPK1 can
shift the equilibrium toward formation of the SRPK1-PHLPP1 heterodimer, which
becomes dominant over the regulatory ternary complex, thus also disabling control of
Akt, and leading to enhanced anchorage-independent cell growth (24).
A number of viruses, such as herpes simplex virus 1 (HSV-1), hepatitis B virus (HBV),
and human papillomavirus (HPV) express proteins that bind to SRPK1, and some of
these interacting proteins can also modulate kinase activity, which shifts host mRNA
processing in favor of viral transcripts (25–27). HSV-1 protein ICP27 was the ﬁrst viral
protein identiﬁed as an SRPK1 regulator. It induces hypophosphorylation of SR proteins
and redistribution of the kinase into the nucleus (27). To facilitate viral replication, ICP27
plays a central role by interacting with and hijacking cellular proteins that function
throughout the RNA maturation process (28). Most HSV-1 genes lack introns and are
inefﬁciently expressed without the action of ICP27, which promotes their expression in
favor of intron-containing cellular transcripts (29–33). HSV-1 ICP27 and its HSV-2
homolog can trigger alternative splicing of speciﬁc transcripts (34–37). ICP27 contains
a C-terminal region called the ICP27 homology domain, which is a conserved globular
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domain that mediates homo-oligomerization (38–42) (Fig. 1A), which interacts with
cellular proteins that function in RNA transcription and export, including SR proteins
(27, 28, 43). The N-terminal domain of ICP27 is an intrinsically disordered region (IDR),
which contains short binding motifs such as for the TREX protein ALYREF (residues 103
to 112) (30, 44) and an RGG box (residues 138 to 152) rich in arginines and glycines that
FIG 1 SRPK1 binds to the RGG box of ICP27 in vitro. (A) Schematic of subdomains and interaction sites within HSV-1 ICP27.
(B) Afﬁnity quantiﬁcation of SRPK1 interaction with unmodiﬁed ICP27103–155. (C) As in panel B but with methylated
ICP27103–155. (D) 1H-15N correlation spectra of [15N]ICP27103–155 in the absence (red) and presence (blue) of a stoichiometric
equivalent of SRPK1. (E) Binding site mapped by analysis of relative signal intensity change upon binding, IB/IF. The
decrease in signal intensity of a protein occurs upon interaction with SPRK1.
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was shown to be necessary for RNA and SRPK1 interactions (27, 45–48). Posttransla-
tional modiﬁcations within the RGG box carried out by PRMT1 (protein arginine
methyltransferase 1), which result in methylation of R138, R148, and R150 (48–50),
modulate SRPK1 interactions (51); however, the details of the ICP27-SRPK1 interaction
and therefore the reason for this modulation were not identiﬁed. The N-terminal IDR of
ICP27 also contains both nuclear export and nuclear localization sequences that
facilitate nuclear-cytoplasmic shuttling, particularly in later stages of HSV-1 infection
(33, 47, 52, 53). In uninfected cells, SRPK1 is predominately cytoplasmic (54); however,
HSV-1 infection and the subsequent interaction of ICP27 with SRPK1 shift the latter into
the nucleus, resulting in SR protein hypophosphorylation and disrupted spliceosome
assembly, thus indicating SRPK1 could be inhibited by ICP27 (27). As the molecular
details of the ICP27-SRPK1 complex and the mechanism of kinase modulation and the
precise role of the RGG box were unknown, we have characterized its structure and
explored the interaction via biophysical and in vivo techniques to gain insights into the
mode of action of the viral protein.
RESULTS
Mapping and quantiﬁcation of SRPK1 binding to ICP27 peptide fragments
containing the RGG box motif. The RGG box in full-length ICP27 (Fig. 1A) was
previously identiﬁed by mutagenesis experiments as the segment necessary for inter-
action with SRPK1 (27), with the binding modulated by arginine methylation (51). To
determine if the isolated RGG box motif can bind SRPK1, we obtained a synthetic
peptide of ICP27103–155, which comprises the RGG box plus the adjacent ALYREF-
binding and NLS regions (Fig. 1A), and puriﬁed full-length SRPK1 tagged with an
N-terminal GB1 solubility tag (GB1-SRPK1). Their interaction was measured by isother-
mal titration calorimetry (ITC), which indicated a Kd (dissociation constant) of
94 23 nM (Fig. 1B; see Table S1 in the supplemental material). The experiment was
also performed with a synthetic peptide methylated within the RGG box at arginine
positions 138, 148 and 150, which weakened the interaction 3-fold with a Kd of
262 21 nM (Fig. 1C; see Table S2 in the supplemental material). To further conﬁrm
and map the RGG box interaction with SRPK1, we expressed and puriﬁed 15N-labeled
ICP27103–155 and using the established backbone assignment (55) carried out nuclear
magnetic resonance (NMR) signal perturbation mapping by comparison of 1H-15N
correlation spectra in the presence and absence of unlabeled GB1-SRPK1 (Fig. 1E). The
data showed substantial signal broadening, typical of somewhat dynamic binding of
parts of the polypeptide chain to a slowly tumbling high-molecular-weight species
(Fig. 1D), particularly within ICP27 residues 112 to 121 and 138 to 152, the latter
comprising the RGG box. These solution data together conﬁrmed that SRPK1 binds with
high afﬁnity to a relatively short region of ICP27 containing the RGG box, with possible
further contributions from nearby residues 112 to 121, whereas other residues retain
signiﬁcant ﬂexibility when the peptide is bound. The ITC measurement of 94 23 nM
is comparable to 50 25 nM reported previously for RS domain binding of a native
substrate, SRSF1, determined using in vitro phosphorylation assays (9–11).
NMR directly conﬁrms competition between SRSF1 and ICP27103–155 for SRPK1
binding. Both the viral RGG box and RS domain found in the native cellular substrate
SRSF1 bear some superﬁcial sequence similarity (i.e., both are arginine-rich), although
only the RS domain is a substrate for the SRPK1 kinase and becomes phosphorylated
(5, 6). Our measurements using ITC and the data from the literature (9–11) do suggest
that the binding of the RGG box regions of ICP27 and the RS domain of SRSF1 with
SRPK1 may be comparable, but which of them is stronger, and whether they are
competitive with each other, needed to be established under identical experimental
conditions. To explore if these two proteins bind SRPK1 competitively, we used a direct
approach, in which all three proteins, in differentially labeled forms, were mixed
together in stoichiometric amounts, and isotopically discriminated (IDIS)-NMR (56) was
used to detect which of the protein complexes is formed preferentially. Initial control
1H-15N heteronuclear single quantum coherence (HSQC) and transverse relaxation-
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optimized spectroscopy (TROSY) experiments established ﬁngerprint spectra of uni-
formly 15N-labeled full-length SRSF1, acquired in the presence and absence of unla-
beled GB1-SRPK1. These characteristic spectral patterns enabled us to recognize the
presence of SRSF1-SRPK1 complex in solution. The SRSF1 spectrum was dominated by
sharp poorly dispersed amide signals typical of IDRs, especially those from the SR
repeats, while lower-intensity dispersed amide signals could be observed in TROSY
spectra typical of folded globular regions (see Fig. S1 in the supplemental material).
Upon addition of GB1-SRPK1, the SR repeat signals were broadened, substantially
FIG 2 IDIS-NMR experiments (56) indicate competition for SRPK1 binding between SRSF1 and the RGG box region of ICP27. Reporter signals for SRPK1 binding
are shown for (A) RGG box within [13C, 15N]ICP27103–155 and (B) RS region from full-length [15N]SRSF1. (i) ICP27 or SRSF1 in isolation, (ii) ICP27 or SRSF1 with
half a stoichiometric equivalent of unlabeled GB1-SRPK1 added, (iii) 1:1 mixture of ICP27 and SRSF1, (iv) 1:1:0.5 mixture of ICP27, SRSF1 and GB1-SRPK1, (v) 1:1:1
mixture of ICP27, SRSF1, and GB1-SRPK1. The normalized relative intensities of reporter signals Irel measured from the spectra shown in panels A and B are
plotted in panel C for ICP27 and panel D for SRSF1. The decrease in signal intensity of a protein occurs upon interaction with SPRK1, and comparison of signals
from ICP27 and SFSR1 within the same sample tube therefore provides an indication of binding preference. The central scheme illustrates the binding scenarios
for each sample, with GB1-SRPK1, ICP27103–155, and SRSF1 molecules colored gray, blue, and red, respectively.
The SRPK1-ICP27 Interaction ®
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weakening their signal intensity along with several other peaks from the IDRs (Fig. 2).
The ICP27103–155 mapping experiment described earlier acted as a reference for the
signal pattern, which was characteristic for SRPK1 binding to the RGG box (Fig. 1):
observing similar characteristic signal patterns in multicomponent protein mixtures
enables us to infer the presence of the SRPK1-RGG box complex. For the following
IDIS-NMR experiments, a stoichiometric mixture of differentially labeled 50 M
[13C,15N]ICP27103–155 and 50 M [15N]SRSF1 was ﬁrst prepared, and spectra were
recorded, which showed only minor signal perturbations compared to the proteins in
isolation, indicating that residues 103 to 155 of ICP27 do not interact with SRSF1 (Fig. 2
[full spectra in Fig. S2 and Fig. S3 in the supplemental material]). Addition of a
substoichiometric amount (25 M) of nonlabeled GB1-SRPK1 resulted in strong signal
perturbations in SRSF1 SR repeat signals, whereas in ICP27, the RGG box signals were
relatively unperturbed, indicative of preferential binding of SRPK1 to the RS domain of
SRSF1. This was also evident by comparison of the signal intensities measured relative
to the nonbound proteins at the middle point of this titration, where SRSF1, ICP27, and
SRPK1 were mixed in a stoichiometric ratio of 1:1:0.5, as the SRSF1 signal is clearly much
weaker than ICP27 (Fig. 2C and D). Addition of more GB1-SRPK1 up to 50 M ﬁnal
concentration produced a stoichiometric ternary mixture (1:1:1) of SRPK1, SRSF1, and
ICP27103–155, resulting in some further SRSF1 SR signal broadening while signiﬁcantly
inducing substantial ICP27 RGG box broadening. The further changes observed partic-
ularly were suggestive of SRPK1 binding to the RS domain approaching saturation
alongside signiﬁcant binding to the RGG box. Together the data indicate that although
SRPK1 has a marginal preference for the SR regions of full-length SRSF1 over a short
ICP27103–155 peptide, the latter is still able to compete for SRPK1 binding (Fig. 2C and
D). This experiment, in which all three proteins are present at equal concentration in
solution and are allowed to compete for binding with each other, demonstrates the
presence of this competition directly.
The crystal structure of ICP27 RGG box peptide bound to the docking groove
of SRPK1. Having demonstrated that the peptide encompassing the ICP27 RGG box
motif can directly bind to SRPK1 and is sufﬁcient for high-afﬁnity binding, we deter-
mined the structure of the complex by X-ray crystallography. The SRPK1 ΔNS1 protein
construct, which was used previously for crystallization studies (7, 8, 57), was puriﬁed
and incubated with ICP27137–152 RGG box peptides. Separate crystal trials using either
unmodiﬁed or methylated peptides were performed, but cocrystallization was only
successful with the unmodiﬁed ICP27137–152 peptide, which diffracted to 2.8 Å (see
Table S3 in the supplemental material). Coordinates were deposited in the Protein Data
Bank, under accession code 6FAD.
The asymmetric unit (ASU) contained four biological assemblies composed of SRPK1
bound to an RGG box peptide. Residues 142 to 148 of ICP27, a 7-mer palindrome,
RGRRRGR, form the majority of the intermolecular contacts with the docking groove of
SRPK1 (Fig. 3), and were observed in all 4 copies of the biological assembly within the
ASU with the same binding mode and residue register. One out of the four copies of
RGG box peptides (chain E) forms additional crystal contacts, in which residues 138 to
141 bind SRPK1 chain D within an adjacent ASU, while residues 142 to 149 form
“typical” contacts with SRPK1 chain A within the same ASU (see Fig. S4 in the
supplemental material), as observed in other copies of the assembly. The complex
formed by chains A and E of SRPK1 and ICP27, respectively, was the most complete and
will be referred to in further discussions (see Table S4 in the supplemental material).
Within SRPK1, four arginine side-chain binding sites were identiﬁed, which contained
R142, R144, R146, and R148 of ICP27 (Fig. 4D): the R142 side chain forms partially buried
ionic contacts with E564 and E571, the R144 side chain is again partially buried and
forms a hydrogen bond with the backbone carbonyl of L550, R146 forms a stacking
interaction with the side chain of W606, and ﬁnally, R148 forms hydrogen bonds with
backbone carbonyls of Q182 and T546. Comparison of the SRPK1-RGG box complex
(Fig. 4D) with other structures of SRPK1 in complex with SRSF1-RRM2 and RS1 domain
(PDB code 3BEG) (Fig. 4E) and membrane-associated guanylate kinase 9-mer docking
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peptide (PDB code 1WBP) (Fig. 4F) indicated that the recognition of the ICP27 peptide
closely resembles these other docking groove complexes. In particular, the arginine
residues from the RS domain of SRSF1 and ICP27 residues R142, R144, R146, and R148
form near-identical polar interactions and salt bridges with SRPK1 (Fig. 4). While the C
terminus of the peptide turns and points toward the active site, it is still positioned
quite far away from the active site, not blocking it directly (Fig. 3B). Speciﬁcally, the C
of G149, which is the C-terminal residue observed in the electron density of the RGG
box, is located approximately 30 Å from the ATP binding pocket of SRPK1. The
similarities in how the docking groove of SRPK1 recognizes stretches of alternating
arginines present both within the native RS domain substrate and the viral RGG box are
striking, and they corroborate the competitive nature of ICP27 and SRSF1 interactions
with SRPK1 observed by IDIS-NMR experiments in solution.
ICP27 RGG box mutants do not interact with or change cellular localization of
SRPK1 in vivo. ICP27 mutants were constructed to target sites within the RGG box that
contact SRPK1 in the crystal structure. Arginines at positions 142, 144, 146, and 148
were changed to glycine (G) as single (R142G, R146G, or R148G), double (R142G R146G),
and quadruple (R142G R144G R146G R148G) substitutions. The ICP27 mutant plasmids
were cotransfected with a plasmid expressing green ﬂuorescent protein (GFP)-SRPK1
and subsequently infected with ICP27 null mutant virus 27-LacZ to recapitulate the
conditions of infection. At 8 h after infection, lysates were immunoprecipitated with
anti-GFP antibody, and samples were analyzed by Western blotting and probed with
antibody to ICP27 (Fig. 5A). Wild-type (WT) ICP27 was efﬁciently coimmunoprecipitated
with GFP-SRPK1; however, this was substantially reduced for ICP27 R142G, R146G, and
FIG 3 Structure of SRPK1 with RGG box peptide ICP27137–152 bound in the substrate docking groove. (A)
Schematic of SRPK1 domains. (B) Crystal structure of the SRPK1 in complex with ICP27137–152. SRPK1 is
colored as panel A, ICP27 is yellow. (C) As in panel A but view rotated 90°. (D) 2Fo  Fc electron density
map of RGG peptide colored blue, contoured to 1 orientated as in panel B.
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R148G single mutants and the R142G R146G double mutant, whereas the R142G R144G
R146G R148G quadruple mutant was not detected even after a longer exposure, as was
the case for the ΔRGG mutant in which the RGG box was deleted (Fig. 5A). ICP27
interaction with endogenous SRPK1 was also analyzed. Cells were transfected with WT
and ICP27 mutant plasmids and infected with 27-LacZ as described above. Immuno-
precipitation was performed with anti-ICP27 antibody and the blots were probed with
antibody to SRPK1 (Fig. 5B). SRPK1 was only coimmunoprecipitated with WT ICP27 and
was not detected with any of the mutants.
Although SRPK1 is predominantly located in the cytoplasm, where it phosphorylates
SR proteins so that they are transported to the nucleus by an SR-speciﬁc transportin
protein, a smaller amount of SRPK1 is also located in the nucleus (21). Also, under some
conditions, SRPK1 nuclear levels become increased. For example, epidermal growth
FIG 4 Comparison of SRPK1 docking groove interactions. (A) Detail of the RGG box peptide bound within the SRPK1 docking groove, plus comparative views
of SRPK1 substrate complexes: (B) SRSF1 RS1 region (8) or (C) 9-mer docking peptide of membrane-associated guanylate kinase (7). SRPK1 is shaded gray, and
bound peptides are colored. Intermolecular hydrogen bonds or salt bridges are represented by red dashes. Chemical schematics of the interactions shown in
panels A to C are shown in panels D to F, respectively.
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factor signaling increases nuclear levels of SRPK1 through the Akt-dependent release of
chaperones from the spacer insert domain of SRPK1, which appears to restrict SRPK1 to
the cytoplasm (58). It was previously shown that during HSV-1 infection ICP27 relocal-
izes SRPK1 from the cytoplasm to the nucleus and the RGG box is required for this
relocalization (27, 51). To determine if the ICP27 RGG box mutants were able to
relocalize SRPK1, cells were cotransfected with GFP-SRPK1 and WT or ICP27 mutant
plasmids and were subsequently infected with 27-LacZ, and 6 h later, cells were ﬁxed
and stained for immunoﬂuorescence analysis. In mock-infected cells and cells infected
with 27-LacZ, SRPK1 was predominantly cytoplasmic, whereas in WT HSV-1 KOS in-
fected cells, SRPK1 was also clearly localized in the nucleus (Fig. 5C). In cells transfected
with WT ICP27 plasmid and infected with 27-LacZ, SRPK1 was seen to be prominently
nuclear. In contrast, SRPK1 was largely cytoplasmic in cells transfected with the R142G,
R146G, R142G R146G, and R142G R144G R146G R148G mutants, similar to what was
observed for ΔRGG-, mock-, and 27-LacZ-infected cells (Fig. 5C). As low levels of SRPK1
are usually present in the nucleus of uninfected cells, some weak colocalization can be
observed—for example, with R142G; however, it is clear that SRPK1 was not efﬁciently
recruited to the nucleus by ICP27 RGG box mutants. Similar results were seen at 4 and
8 h after infection (data not shown).
We showed previously that ICP27 inhibited SRPK1 phosphorylation of SR proteins
via in vitro SRPK1 kinase assays, and the interaction of ICP27 and SRPK1 resulted in
hypophosphorylation of SR proteins in vivo (27). To determine how the ICP27 RGG box
mutants would affect SR protein phosphorylation in vivo, cells were cotransfected with
GFP-SRPK1 and WT ICP27 or ΔRGG, R142G R144G R146G R148G, and R142G R146G
mutants and were subsequently infected with 27-LacZ (Fig. 5D). Western blots were
probed with an anti-phosphoepitope SR protein antibody that recognizes phosphory-
lated serines within SR repeats. The level of phosphorylation for SRp40 (SRSF5) was
reduced in cells transfected with WT ICP27, but not in those transfected with the
mutants (Fig. 5D). Similarly, phosphorylation of SRp30 (SRSF1) was reduced with WT
ICP27, indicating it was hypophosphorylated in the presence of ICP27 but not by the
ICP27 RGG box mutants, which do not interact with SRPK1 and do not relocalize SRPK1
to the nucleus (Fig. 5D). The blot was probed with antibody to SRSF1, which showed
that levels of endogenous SRSF1 were similar, so the reduced phosphorylation ob-
served was not because of reduced expression. Thus, while WT ICP27 inhibits SRPK1
activity in vivo, resulting in hypophosphorylated SR proteins, RGG box mutants do not
interact with SRPK1 and do not promote hypophosphorylation.
FIG 5 ICP27 RGG box mutants do not interact with SRPK1 and do not inhibit its activity in vivo. HeLa cells cotransfected with GFP-SRPK1 and WT ICP27 or RGG
box mutants were infected for 8 h with 27-LacZ. Immunoprecipitation was performed using anti-GFP antibody. Western blots were probed with anti-GFP or
anti-ICP27 antibody and anti--actin as a loading control. (B) HeLa cells transfected with WT and ICP27 RGG box mutants were infected with 27-LacZ for 8 h.
Immunoprecipitation was performed with anti-ICP27 antibody. Western blots were probed with anti-SRPK1 or anti-ICP27 antibody as indicated and anti--actin
as a loading control. (C) RSF cells were transfected with GFP-SRPK1 and 16 h later were mock infected, infected with WT HSV-1 or 27-LacZ, or were cotransfected
with GFP-SRPK1 and WT ICP27 or ICP27 RGG box mutants and infected 16 later with 27-LacZ. Cells were ﬁxed 6 h later and immunoﬂuorescent staining was
performed with anti-ICP27. ICP4 antibody was used to stain the 27-LacZ sample to mark the nucleus. GFP ﬂuorescence was visualized directly. The panels shown
are representative of 80% of cells visualized. (D) HeLa cells were transfected with GFP-SRPK1 and WT ICP27 or RGG box mutants and were infected with
27-LacZ 16 h after transfection for 8 h. Portions of cell lysates were fractionated by SDS-PAGE, and Western blots were probed with antiphosphoepitope SR
antibody, anti-SF2 (SRSF1), anti-ICP27 antibody, and anti-lamin B1 antibody as a loading control.
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DISCUSSION
The activity of the cellular protein SRPK1 is central to maintaining the correct level
of phosphorylation of SR proteins, which in turn allows efﬁcient splicing (3). Imbalances
in posttranslational modiﬁcation of SR proteins in cells harboring SRPK1 mutants not
only affect splicing efﬁciency and alternative splicing but is also a disease phenotype in
certain cancers and therefore the inhibition of SRPK1 is a drug target (1, 2). A number
of viruses such as HSV-1, HBV, and HPV express proteins that bind to SRPK1 as the
substrates, and some of these interacting proteins can also modulate kinase activity,
which shifts host mRNA processing in favor of viral transcripts (25–27). HSV-1 ICP27 was
the ﬁrst viral protein identiﬁed as an SRPK1 regulator. It induces hypophosphorylation
of SR proteins and redistribution of the kinase into the nucleus (27). The RGG box motif
of ICP27 was identiﬁed as a requirement for SRPK1 interactions, and arginine methyl-
ation was shown to modulate the binding (51). However, it was not established
whether this motif in its isolated form is sufﬁcient for the interaction, nor was the
molecular mechanism of inhibition elucidated. It was not known whether the binding
occurs in a competitive manner relative to the substrate or is allosteric and whether
other parts of the ICP27 protein contribute to the interaction interface. Here, we have
established the molecular basis of SRPK1 interactions with ICP27 and characterized the
role of the RGG box. The biophysical data indicated that the RGG box can indepen-
dently interact with SRPK1, with an afﬁnity similar to that of a native full-length
substrate SRSF1 (Fig. 1). Competition between the ICP27103–155 peptide, which contains
the RGG box and SRSF1 for binding to SRPK1 was observed directly by solution NMR
(Fig. 2). The crystal structure revealed that the RGG box binds to the substrate docking
groove (Fig. 3), in the same place where the SR repeats of the native substrate bind and
in a conﬁguration similar to that of a substrate (Fig. 4). The ITC experiments indicated
that methylation of the RGG box at positions R138, R148, and R150 lowered afﬁnity for
SRPK1, and the structure provides an explanation for this. Within an unmodiﬁed RGG
box, the side chains of R142, R144, and R148 become buried upon interaction with
SRPK1; methylation at these positions is likely to introduce steric clashes, thus reducing
binding afﬁnity. Also if the RGG box interaction with SRPK1 is mediated in part by a
sliding mode in order to search for an optimal residue register, in a manner analogous
to the processive phosphorylation mechanism, then methylation may also interfere
with transient binding events that facilitate sliding within the docking groove. Immu-
noprecipitation experiments analyzing SRPK1 interaction with full-length ICP27 further
supported the necessity for an intact RGG box sequence for efﬁcient interaction of the
proteins and the resultant hypophosphorylation of SR proteins in vivo (Fig. 5). Addi-
tionally immunoﬂuorescence data indicated that the cellular redistribution of SRPK1 by
ICP27 is dependent on the RGG box, and single point mutations of arginines are
sufﬁcient to perturb SRPK1 relocalization. The inhibitory action of full-length ICP27
appeared effective in the immunoprecipitation experiments, which was also previously
demonstrated via in vitro kinase assays (27).
In the context of infection, ICP27 appears to play a dual role in inhibiting SRPK1
action on SR protein substrates. First, the ICP27 RGG box is able to directly compete
with RS domains for the docking groove of SRPK1, and we speculate that additional
regions of ICP27 may further enhance afﬁnity for SRPK1. Second, the redistribution of
SRPK1 to the nucleus by ICP27 may prevent contact of the kinase with hypophosphor-
ylated SR proteins, which are typically imported after phosphorylation into the nucleus.
Therefore, through a high-afﬁnity interaction, ICP27 is able to regulate the activity and
cellular distribution of SRPK1, thus preventing the phosphorylation of SR proteins and
disrupting host splicing. While global transcriptome sequencing (RNA-seq) studies have
shown that ICP27 inhibits splicing of certain introns in cellular genes and also can
promote the use of alternative 5= splice sites in cellular pre-mRNAs (37), the advantages
to viral infection have been less clear. Recently, it was shown through global analysis
of splice junctions in cells infected with HSV-1 that there are hundreds of novel
alternative splice junctions mapping to known HSV-1 spliced genes and previously
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unknown spliced genes, the majority of which alter the coding potential of viral genes.
Splicing efﬁciency of the novel alternatively spliced genes revealed that splicing at the
novel splice sites was efﬁcient only in an HSV-1 ICP27 deletion mutant virus infection.
In WT HSV-1-infected cells, splicing of the novel splice junctions was mainly silenced in
a gene- and sequence-speciﬁc manner, suggesting that ICP27’s effects on host cell
splicing ensure accuracy of the functional coding sequences of viral genes through
inhibition of alternative splicing (59). Thus, the interaction of ICP27 with SRPK1 and the
subsequent inhibition of splicing have important and previously unappreciated con-
sequences on viral gene expression.
MATERIALS AND METHODS
Protein expression and puriﬁcation. The proteins glutathione S-transferase (GST)-ICP27103–155,
GB1-SRPK1, and SRPK1 ΔNS1 were expressed in Escherichia coli. Proteins were puriﬁed by standard GST
or His tag puriﬁcation methods followed by size exclusion chromatography. Further details are provided
in Text S1 in the supplemental material.
Synthetic peptides. Peptides for the ICP27 RGG box used in crystallization experiments were
produced by EZBiolab (Carmel, IN, USA) comprised ICP27 residues 137 to 152 (sequence ARGGRRGRRR
GRGRGG), in two forms: unmodiﬁed standard L-peptide and methylated with asymmetric dimethylation
on R138, R148, and R150. Peptides used for ITC comprising ICP27 residues 103 to 155 in unmodiﬁed form
and dimethylated on R138, R148, and R150 as described above were produced by Peptide Protein
Research (Hampshire, United Kingdom).
Crystallization. To generate complexes of SRPK1 ΔNS1 with RGG box peptide ICP27137–152 (ICP27
residues 137 to 152) for crystallography puriﬁed 2 M SRPK1 ΔNS1 was combined with a 6 M peptide
and incubated for 16 h at 4°C. Complex was puriﬁed using a Superdex 75 10/300 column equilibrated
with buffer supplemented with 1 M ICP27137–152 peptide. Protein concentrated to 260 M grew crystals
by sitting drop vapor diffusion at 4°C when mixed 1:1 with a reservoir solution of 0.09 M [NaNO3, 0.3
Na2HPO4, 0.3 M (NH4)2SO4], 0.1 M (sodium HEPES, MOPS [morpholinepropanesulfonic acid]) buffer
system (pH 7.5) with 50% vol/vol GOL_P4K mix (Morpheus HT96 C7; Molecular Dimensions). Crystals were
ﬂash frozen by plunge freezing in liquid nitrogen. Further details are provided in Text S1.
Data collection, structure determination, model building and reﬁnement. Data were collected
from single cryo-frozen crystal SRPK1 ΔNS1-RGG box at beamline i04-1 (Diamond Light Source). Data
were indexed, scaled and integrated with Xia2 (60). Phases were determined by molecular replacement
using phaser with coordinates from Protein Data Bank code 1WAK (61). An automated model built
against the phased map in Phenix AutoBuild was used as the basis for iterative cycles of rebuilding and
reﬁnement in COOT and Phenix.reﬁne (62, 63), with validation with MolProbity and PDB_REDO (64, 65).
ICP27 RGG box peptides were initially built as polyalanine to ensure unbiased identiﬁcation of the correct
register of residues. Table S3 lists data collection and reﬁnement statistics. Cocrystallization of SRPK1
ΔNS1-RGG box was only successful with the unmodiﬁed ICP27137–152 peptide, which diffracted to 2.8 Å
(Table S3). Coordinates were deposited in the Protein Data Bank under accession code 6FAD.
Nuclear magnetic resonance. Uniformly 13C, 15N-labeled ICP27103–155 backbone amide signal (BMRB
accession no. 27341 [55]) perturbations were monitored upon additional of unlabeled GB1-SRPK1.
Similarly, uniformly 15N-labeled SRSF1 backbone amide signals signal perturbations in 1H-15N HSQC
spectra of SRSF1 were monitored upon additional of unlabeled GB1-SRPK1. For IDIS-HSQC-NMR exper-
iments (56), a sample was prepared containing a 1:1 mixture of differentially labeled proteins, speciﬁcally
50 M 13C, 15N-labeled ICP27103–155 and 50 M 15N-labeled SRSF1. IDIS-HSQC spectra were acquired of
this 1:1 mixture and then with unlabeled GB1-SRPK1 added to 25 M and then to 50 M. Data were
processed in Topspin (Bruker) and analyzed in Sparky (66). Further details are in Text S1.
Isothermal titration calorimetry. GB1-SRPK1 and ICP27 peptides were placed into Slide-a-Lyzer G2
cassettes (Thermo Fisher) and dialyzed within identical buffer consisting of 20 mM HEPES, 150 mM NaCl,
and 1 mM TCEP [Tris(2-carboxyethyl)phosphine hydrochloride] (pH 7.4). Protein concentrations were
measured by absorbance at 280 nm using extinction coefﬁcients (67) of 86,580 M1 cm1 and 5,500 M1
cm1 for GB1-SRPK1 and ICP27103–155, respectively. Experiments were performed at 25°C on a PEAQ-ITC
(Malven instruments), using 10 M GB1-SRPK1 in the sample cell and 120 M ICP27 peptide in the
syringe. Each experiment consisted of 19 injections: the ﬁrst at 0.4 l and the rest at 2 l. Data were
processed and ﬁtted to a single-site binding model with Microcal PEAQ-ITC analysis (V1.00.1262).
In vivo studies. For immunoprecipitation experiments, HeLa cells grown on minimal essential
medium containing 10% newborn calf serum were infected with HSV-1 wild-type strain KOS or null
mutant 27-LacZ as described previously (39). Transfection of plasmid DNA was performed with Lipo-
fectamine 2000 (Invitrogen). Cells were infected with 27-LacZ 24 h after transfection to stimulate
expression of the native ICP27 promoter by the virion tegument protein VP16 as previously described
(39, 68). Cells were harvested 8 h later, and immunoprecipitation was performed using GFP antibody
Ab290 (Abcam) or ICP27 monoclonal antibody P1119 (Virusys) as described previously (39). Western blots
were probed with anti-ICP27 antibody P1119, anti-GFP antibody JL-8 (TaKaRa Bio), or anti--actin
antibody.
In immunoﬂuorescence experiments, rabbit skin ﬁbroblasts (RSF) were transfected and/or infected as
indicated in the legend to Fig. 5. At 8 h after infection, cells were ﬁxed in 3.7% formaldehyde, and
immunoﬂuorescent staining was performed as previously described (43) with ICP27 antibody P1119 or
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ICP4 (P1114 [Virusys]). GFP ﬂuorescence was viewed directly. Cells were viewed with a Zeiss Axiovert
S100 microscope.
For in vivo phosphorylation analysis, HeLa cells were transfected with GFP-SRPK1 and ICP27 RGG box
mutants, as indicated in Fig. 5D, and 24 h after transfection, cells were infected with 27-LacZ for 8 h. To
monitor SR protein phosphorylation, 5% of each cellular lysate was resolved by SDS-PAGE. Western blot
analysis was performed with antiphosphoepitope SR antibody MABE50 (Millipore), anti-SF2 (SRSF1)
antibody ab38017 (Abcam), anti-ICP27 antibody P1119, and anti-lamin B1 antibody.
Data availability. Cocrystallization of SRPK1 ΔNS1-RGG box coordinates have been deposited in the
Protein Data Bank, under accession code 6FAD.
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